SPONSOR
Proton Collaborative Group
Total Trials
2
Recruiting
2
Phases
Phase 2, Phase 3
Proton Collaborative Group is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Pancreatic Cancer, Prostate Cancer.
The trial portfolio spans Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Proton Collaborative Group
How many clinical trials has Proton Collaborative Group sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Proton Collaborative Group, of which 2 are actively recruiting participants. These trials cover conditions including Pancreatic Cancer, Prostate Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Proton Collaborative Group research focus on?
Proton Collaborative Group clinical trials span Pancreatic Cancer, Prostate Cancer. The research pipeline includes Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Proton Collaborative Group clinical trial?
To participate in a Proton Collaborative Group trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Proton Collaborative Group trials with current recruitment status updated daily.
Clinical Trials by Proton Collaborative Group
NCT02598349 Phase 2
Recruiting
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Pancreatic Cancer
NCT01492972 Phase 3
Recruiting
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Prostate Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology